A systematic review and meta-analysis of randomized controlled head-to-head trials of recommended drugs for neuropathic pain
Open Access
- 21 February 2024
- journal article
- review article
- Published by Wolters Kluwer Health in Pain Reports
- Vol. 9 (2) , e1138
Abstract
Neuropathic pain is a challenging chronic pain condition. Limited knowledge exists regarding the relative effectiveness of pharmacological treatments, and differences in trial design and impact of the placebo response preclude indirect comparisons of efficacy between drug classes. The purpose of this systematic review and meta-analysis of head-to-head trials was to compare the efficacy and tolerability of drugs recommended for neuropathic pain. We conducted a systematic review and meta-analysis of direct-comparison double-blind randomized trials. Primary outcomes were mean change in pain intensity and number of responders with a 50% reduction in pain intensity. Secondary outcomes encompassed quality of life, sleep, emotional functioning, and number of dropouts because of adverse events. We included 30 trials (4087 patients), comprising 16 crossover and 14 parallel-group design studies. All studies were conducted in adults, and the majority were investigator-initiated trials. We found moderate-quality evidence for equivalence (no clinically relevant difference) between tricyclic antidepressants (TCA) and gabapentin/pregabalin with a combined mean difference in pain score of 0.10 (95% CI −0.13 to 0.32). We could not document differences between TCA and serotonin–noradrenaline reuptake inhibitors (SNRI), between SNRI and gabapentin/pregabalin, or between opioids and TCA (low quality of evidence). We found more dropouts because of adverse events with SNRI and opioids compared with TCA (low quality of evidence). We did not identify any studies that included topical treatments. This systematic review of direct-comparison studies found evidence for equivalence between TCA and gabapentin/pregabalin and fewer dropouts with TCA than SNRI and opioids.Keywords
Funding Information
- Lundbeck Foundation (R359 to 2020 to 2620)
- Novo Nordisk Fonden (NNF20OC0065520)
This publication has 59 references indexed in Scilit:
- Comparison of the Efficacy and Safety of Pregabalin and Duloxetine in Taxane-Induced Sensory Neuropathy: A Randomized Controlled TrialClinical Drug Investigation, 2020
- Efficacy and safety of duloxetine and Pregabalin in Iranian patients with diabetic peripheral neuropathic pain: a double-blind, randomized clinical trialJournal of Diabetes & Metabolic Disorders, 2019
- Effect of Gabapentin vs Pregabalin on Pain Intensity in Adults With Chronic SciaticaJAMA Neurology, 2019
- Are placebo and drug-specific effects additive? Questioning basic assumptions of double-blinded randomized clinical trials and presenting novel study designsDrug Discovery Today, 2017
- Association Between Analytic Strategy and Estimates of Treatment Outcomes in Meta-analysesJAMA, 2014
- Emergence of Large Treatment Effects From Small Trials2013
- The evidence provided by a single trial is less reliable than its statistical analysis suggestsJournal of Clinical Epidemiology, 2009
- Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analysesJournal of Clinical Epidemiology, 2008
- Comparison of the Effectiveness of Amitriptyline and Gabapentin on Chronic Neuropathic Pain in Persons With Spinal Cord InjuryArchives of Physical Medicine and Rehabilitation, 2007
- Randomized Double-blind Study Comparing the Efficacy of Gabapentin With Amitriptyline on Diabetic Peripheral Neuropathy PainArchives of internal medicine (1960), 1999